2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1582

The Association of Lupus Nephritis Histopathologic Classification with Venous Thromboembolism Is Modified by Age at Biopsy
Abstract Number: 2188

The Association of Plasma Fatty Acids Levels with Hand and Knee Osteoarthritis
Abstract Number: 1681

The Association of Reduced Low-Density Lipoprotein (LDL) Cholesterol Levels with ANCA-Associated Vasculitis (AAV)
Abstract Number: 878

The Association of Serum Magnesium with Chondrocalcinosis and Osteoarthritis
Abstract Number: 2073

The Association of Serum Uric Acid Levels and the Risk of Lower Urinary Tract Symptoms in Korean Healthy Adults
Abstract Number: 391

The Beneficial Effects of Rituximab Treatment in Myositis May Be Due to the Binding of a Non B-Cell Protein, SMPDL3B, in Skeletal Muscle
Abstract Number: 179

The Burden of Comorbidity in Patients with RA, PSA or SPA in a General Practice Registry
Abstract Number: 1773

The Card9-Neutrophil Signaling Axis Is Critical to Induction of Th17-Mediated Arthritis in SKG Mice
Abstract Number: 2703

The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Patient Characteristics, Patient Reported Outcomes and Consensus Treatment Plan Choices
Abstract Number: 764

The Clinical and Angiographic Features of Chinese Takayasu’s Arteritis Patients: A Cohort Study of 591 Patients in 6 Years
Abstract Number: 137

The Clinical and Laboratory Characteristics of Antiphospholipid Antibody Positive Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Abstract Number: 195

The Clinical Characteristics of Patients with Inflammatory Arthritis and a Persistently Low Alkaline Phosphatase Level in a Veteran Affairs Rheumatology Clinic
Abstract Number: 1637

The Clinical Features of Anti-RNA Polymerase III Antibodypositive Systemic Sclerosis with and Without Malignancy
Abstract Number: 1647

The Collaborative National Quality and Efficacy Registry for Scleroderma: Data Completion Outcomes from a Multicenter United States Cohort Using Guideline-Based Registry Practices
Abstract Number: 148

The Combat Rheumatologist: Long Term Professional Outcomes of Graduates from a Tri-Service Military Rheumatology Fellowship Program

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].